文献速递前列腺癌膀胱癌与上尿路尿路上皮癌肾癌与肾肿瘤

人工智能在泌尿生殖系统肿瘤中的应用:发表趋势与系统综述

Artificial intelligence in genitourinary oncology: publication trends and systematic review.
PubMed 文献 · BJU Int · 2026-06-26

该研究分析了2013至2023年人工智能在泌尿生殖系统肿瘤领域的发表趋势,并对随机对照试验(RCT)进行了系统综述。共纳入1220篇文章,其中仅4项RCT,分别涉及尿路上皮癌和前列腺癌;文献数量从2013年的14篇增长至2023年的362篇。现有RCT提示AI在诊断、预后和治療计划方面具有潜力,但高级别证据仍有限。

要点

  • AI在泌尿生殖系统肿瘤领域的文献数量从2013年14篇增至2023年362篇,2019年后加速增长。
  • 共纳入1220篇文章,仅4项RCT,其中2项评估AI诊断性能优于传统方法。
  • 另2项RCT显示AI在预后和治療计划中改善影像解读和操作效率。

核心结论

  • 人工智能在泌尿生殖系统肿瘤领域的研究有所增长,但来自随机对照试验的高级别证据仍然有限。
  • 现有试验强调AI在诊断、预后和治療计划方面的前景,该领域快速演变需要持续的前瞻性研究。

研究设计与样本

  • 检索MEDLINE、EMBASE和CINAHL数据库,排除非英文、非人类研究、综述及仅用AI写作的文章。
  • 分析2013至2023年发表趋势,按研究设计和癌症类型分类。
  • 对随机对照试验进行系统综述,使用Covidence筛选和数据提取,两名评审独立评估,采用Cochrane RoB 2.0工具评估偏倚风险。

主要发现

  • 共识别2409篇文章,1220篇符合纳入标准,包括962篇回顾性研究、175篇前瞻性研究、79篇混合设计研究和4项RCT。
  • 研究最常涉及前列腺癌(n=923)、肾癌(n=274)和尿路上皮癌(n=194)。
  • 发表数量从2013年的14篇增长至2023年的362篇,2019年大幅加速。
  • 4项RCT中,1项在尿路上皮癌,3项在前列腺癌;2项评估AI诊断性能优于传统方法,2项评估AI在预后和治療计划中改善影像解读和操作效率。
  • 偏倚风险因研究而异,主要与随机化和偏离预期干预有关。

临床怎么用

  • 临床医生应了解AI在泌尿生殖系统肿瘤诊断、预后和治療计划中的潜在应用,但需注意高级别证据有限。
  • 在临床实践中应用AI工具时,应关注其证据等级,优先参考随机对照试验结果。

局限性

  • 仅纳入英文文献,可能遗漏非英文研究。
  • 随机对照试验数量少(仅4项),高级别证据有限。
  • 偏倚风险因研究而异,主要与随机化和偏离干预有关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To conduct an analysis of publication trends and a systematic review of randomized controlled trials (RCTs) to characterize the current state of artificial intelligence (AI) use in genitourinary (GU) oncology, as AI has emerged as a transformative tool in healthcare with potential applications in diagnostics, treatment planning, and prognostication. METHODS: We searched the Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica dataBASE (EMBASE; Ovid), and Cumulative Index to Nursing and Allied Health Literature (CINAHL) Ultimate for studies related to AI and GU oncology, excluding non-English papers, non-human studies, review articles, and articles using AI solely for manuscript writing. Publication trends were analysed from 2013 to 2023 and categorized by study design and cancer type. RCTs were evaluated through systematic review using Covidence (Veritas Health Innovation Ltd, Melbourne, Victoria, Australia) for screening and data extraction. Two reviewers independently assessed all studies, with risk of bias (RoB) evaluated using the Cochrane RoB 2.0 tool. RESULTS: Of 2409 articles identified, 1220 met inclusion criteria. These included 962 retrospective articles, 175 prospective studies, 79 studies with combined retrospective/prospective methods, and four RCTs. Studies most commonly addressed prostate (n = 923), renal (n = 274), and urothelial (n = 194) cancers. Publications grew from 14 in 2013 to 362 in 2023, with substantial acceleration in 2019. Four RCTs were identified - one in urothelial cancer and three in prostate cancer. Two RCTs evaluated AI-based diagnostics, demonstrating improved performance over conventional methods; the remaining two RCTs evaluated AI in prognostication and treatment planning, showing improved gains in imaging interpretation and operational efficiency. RoB varied across studies, primarily related to randomisation and deviations from intended interventions. CONCLUSIONS: Artificial intelligence research in GU oncology has grown, although high-level evidence from RCTs remains limited. Existing trials underscore AI's promise in diagnostics, prognostication, and treatment planning, and the rapidly evolving nature of this field warrants continued prospective investigation.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Kim A, Moore NA, Dong T, et al. Artificial intelligence in genitourinary oncology: publication trends and systematic review. BJU Int. 2026. PMID: 42360093. doi:10.1111/bju.70361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。